Osimertinib for Uncommon Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Carcinoma: A Case Report

In summary, there are limited prospective data to guide therapy in patients with rare EGFR mutations. Prospective studies are required to evaluate the response to endothelial growth factor receptor-tyrosine kinase inhibitors in patients with rare EGFR mutations in order to ensure patient safety and response to treatment in this patient population.